fulvestrant.md

Fulvestrant

Faslodex inj 250mg/5mL

臨採

TAH Drug Code	IFAS
Indications	Breast cancer, metastatic, breast cancer, advanced or metastatic (second-line endocrine-based combination therapy)
Dosing	500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.
Hepatic Impairment	Dose adjustment required
Renal Impairment	Dose adjustment required
Contraindications	a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema
Adverse Effects	>10%: Central nervous system: Fatigue (8% to 29%), headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%), diarrhea (19%), constipation (5% to 16%), stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis, upper respiratory infection, urinary tract infection, influenza, bronchitis, rhinitis, conjunctivitis, pneumonia, sinusitis, cystitis, oral herpes, respiratory tract infection) Local: Pain at injection site (12%; including neuralgia, peripheral neuropathy, sciatica) 1% to 10%: Dermatologic: Alopecia (6%), skin rash (6%), xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%), anorexia (6%), vomiting (6%), dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%), leukopenia (5%; grade 3: 1%; grade 4: 1%), neutropenia (4%; grade 3: 1%), febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%), arthralgia (8%), back pain (8%), limb pain (7%), musculoskeletal pain (6%), weakness (5% to 6%) Ophthalmic: Blurred vision (2%), dry eye syndrome (2%), increased lacrimation (1%) Respiratory: Cough (5%), dyspnea (4%), epistaxis (2%)
Pregnancy	Contraindicated
Lactation	Contraindicated
More Info	UpToDate